Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.
about
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and RecommendationsData on quantification of signaling pathways activated by KIT and PDGFRA mutants.Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.Tocotrienol Nanoemulsion Platform of Curcumin Elicit Elevated Apoptosis and Augmentation of Anticancer Efficacy against Breast and Ovarian CarcinomasIndividual and Combined Cytotoxic Effects of Co-Occurring Deoxynivalenol Family Mycotoxins on Human Gastric Epithelial Cells.Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action.ALK and IGF-1R as independent targets in crizotinib resistant lung cancer.Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells.Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.The synergistic effect of propofol and ulinastatin suppressed the viability of the human lung adenocarcinoma epithelial A549 cell line
P2860
Q26767798-B8CE16EF-7BA3-46C0-8ED7-DCFA86DE8E71Q31143853-6CDBE1AD-D847-4C27-9866-980FCDF8A9A2Q37075277-EA2E10D9-8503-47F3-9099-5E7F04C330DBQ37465371-2AB0E4D3-CC40-4A34-BB0B-AF7597D16B03Q37727935-1193FFAD-5A09-46FA-BFD8-207A94B76E36Q38665185-C6A41260-3E04-4690-A6C8-3EBE6220B29CQ38707613-DA008137-1936-42B5-A661-957E952E9897Q38724921-ACD41DE1-CE84-4A50-A9FC-2F15B7C2537BQ38725757-44940EBF-350E-496C-87DC-2F1C092072F3Q39006252-AA529D61-DA75-4357-BBDE-CCCEF832DEEEQ41244127-DBA3D6FA-2F99-4734-9FD4-24BBAE841172Q42639671-B8091F98-7BB7-4C19-8DFE-969E8F09345CQ48808585-B4402D64-E8F3-4786-AA22-6ADFAFCBDF88Q50068040-32F99068-6397-4286-84F7-CD5405A33779Q52641490-7495183E-6795-4CEE-8938-41FCA4BBE2FBQ58794878-C9E05CD8-4591-4584-B299-820D33B3B6EF
P2860
Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Drug combination studies and t ...... e Chou-Talalay method--letter.
@en
Drug combination studies and t ...... e Chou-Talalay method--letter.
@nl
type
label
Drug combination studies and t ...... e Chou-Talalay method--letter.
@en
Drug combination studies and t ...... e Chou-Talalay method--letter.
@nl
prefLabel
Drug combination studies and t ...... e Chou-Talalay method--letter.
@en
Drug combination studies and t ...... e Chou-Talalay method--letter.
@nl
P1433
P1476
Drug combination studies and t ...... e Chou-Talalay method--letter.
@en
P2093
John C Ashton
P356
10.1158/0008-5472.CAN-14-3763
P407
P577
2015-06-01T00:00:00Z